Clinicopathological features, MCPyV status and outcomes of Merkel cell carcinoma in solid-organ transplant recipients: a retrospective, multicentre cohort study

Ferrándiz-Pulido, C. (C.); Gómez-Tomás, A. (A.); Llombart, B. (B.); Mendoza, D. (D.); Marcoval, J. (J.); Piaserico, S. (S.); Baykal, C. (C.); Bouwes-Bavinck, J.N. (J.N.); Racz, E. (E.); Kanitakis, J. (J.); Harwood, C.A. (C.A.); Cetkovska, P. (P.); Geusau, A. (A.); Del-Marmol, V. (V.); Masferrer, E. (E.); Orte-Cano, C. (C.); Ricar, J. (J.); de-Oliveira, W.R. (W.R.); Salido-Vallejo, R. (Rafael); Ducroux, E. (E.); Gkini, M.A. (M.A.); López-Guerrero, J.A. (J.A.); Kutzner, H. (H.); Kempf, W. (W.); Seckin, D. (D.)

Issue Date:

2022

ISSN:

0926-9959

Note:

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License

Citation:

Ferrándiz-Pulido, C.; Gómez-Tomás, A.; Llombart, B.; et al. "Clinicopathological features, MCPyV status and outcomes of Merkel cell carcinoma in solid-organ transplant recipients: a retrospective, multicentre cohort study". Journal of the European Academy of Dermatology and Venereology. 36 (11), 2022, 1991 - 2001

Abstract

Background The proportion of Merkel cell carcinomas (MCCs) in solid-organ transplant recipients (SOTR) harbouring Merkel cell polyomavirus (MCPyV) is unknown, as are factors affecting their outcomes. Objective To describe clinicopathological features of MCC in SOTR, investigate the tumoral MCPyV-status and identify factors associated with tumour outcomes. Methods Retrospective, international, cohort-study. MCPyV-status was investigated by immunohistochemistry and polymerase chain reaction. Results A total of 30 SOTR and 44 consecutive immunocompetent patients with MCC were enrolled. SOTR were younger at diagnosis (69 vs. 78 years, P < 0.001). Thirty-three percent of SOTR MCCs were MCPyV-positive vs. 91% of immunocompetent MCCs (P = 0.001). Solid-organ transplantation was associated with an increased cumulative incidence of progression (SHR: 3.35 [1.57-7.14], P = 0.002), MCC-specific mortality (SHR: 2.55 [1.07-6.06], P = 0.034) and overall mortality (HR: 3.26 [1.54-6.9], P = 0.002). MCPyV-positivity and switching to an mTOR inhibitor (mTORi) after MCC diagnosis were associated with an increased incidence of progression (SHR: 4.3 [1.5-13], P = 0.008 and SHR: 3.6 [1.1-12], P = 0.032 respectively) in SOTR. Limitations Retrospective design and heterogeneity of SOTR cohort. Conclusions MCPyV appears to play a less prominent role in the aetiopathogenesis of MCC in SOTR. SOTR have a worse prognosis than their immunocompetent counterparts and switching to an mTORi after the diagnosis of MCC does not improve progression.

URI:

https://hdl.handle.net/10171/65294

DOI:

10.1111/jdv.18256

Appears in Collections:

DA - CUN - Dermatología médico-quirúrgica y venereológica - Artículos de revista

Files in This Item: